Vertex Pharmaceuticals Incorporated (VRTX)


-2.86 (-0.81%)
Strong Buy
Symbol VRTX
Price $351.422
Beta 0.506
Volume Avg. 1.02M
Market Cap 90.700B
Shares () -
52 Week Range 276.57-367.0
1y Target Est -
DCF Unlevered VRTX DCF ->
DCF Levered VRTX LDCF ->
ROE 23.68% Buy
ROA 16.54% Buy
Operating Margin -
Debt / Equity 4.96% Neutral
P/E 27.63 Strong Buy
P/B 5.85 Strong Buy


Consensus EPS

Upgrades & Downgrades

Latest VRTX news

Dr. Reshma Kewalramani FASN, M.D.
NASDAQ Global Select

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6 years of age or older who have at least one F508del mutation. Its pipeline includes VX-864 for the treatment of AAT deficiency, which is in Phase 2 clinical trial; VX-147 for the treatment of APOL1-mediated focal segmental glomerulosclerosis, or FSGS, and other serious kidney diseases which is in Phase 2 clinical trial; VX- 880, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-548, a NaV1.8 inhibitor for treatments of acute, neuropathic, musculoskeletal pain which is in Phase 2 clinical trial; and CTX001 for the treatment severe SCD and TDT which is in Phase 3 clinical trial. The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. It has collaborations with Affinia Therapeutics, Inc.; Arbor Biotechnologies, Inc.; CRISPR Therapeutics AG.; Kymera Therapeutics, Inc.; Mammoth Biosciences, Inc.; Moderna, Inc.; Obsidian Therapeutics, Inc.; and Skyhawk Therapeutics, Inc.; as well as Ribometrix, Inc.; Genomics plc; Merck KGaA; Darmstadt, Germany, and X-Chem, Inc. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.